title: Myelomonocytic antigens in B-cell chronic lymphocytic leukemia.
abstract: The clinical significance of myelomonocytic (MyMo) antigens in B-cell chronic lymphocytic leukemia (B-CLL) is unclear. We have analyzed the expression of MyMo antigens (CD13, CD14 (LeuM3, My4, Mo2), CD15, CD11b, CD11c, CD33 and CD68) on B-lymphocytes (CD19+) in 105 B-CLL patients and in 35 controls. A double direct staining technique and flow cytometric analysis was performed. The expression of MyMo antigens on the control group did not exceed 4% B-lymphocytes. A MyMo antigen was considered as positive when present in > or = 10% of B-lymphocytes. Among the B-CLL patients, 28 (26.7%) were positive for CD11c, 21 (20.0%) for CD11b, nine (8.6%) for CD15, five (4.8%) for CD13, two (1.9%) for Mo2, and one (1.0%) for My4. No patient was positive for LeuM3, CD33 or CD68. CD11c was more frequently expressed in patients with a short lymphocyte doubling time (< 12 months) (P = 0.05) and CD11b in the group with a higher number of lymphoid areas involved (P = 0.02). No correlation was found between lymphoid morphology and MyMo antigen expression. Fourteen of the 80 patients at risk subsequently progressed to a more advanced stage. Multivariate analysis identified hemoglobin (P = 0.004) and CD11b positivity (P = 0.009) as independent variables for disease progression. Fifteen patients died during evolution. Seven out of the 21 CD11b positive patients and eight of the 84 CD11b negative patients died (LR: P = 0.02, BG: P = 0.05). In the multivariate analysis, only CD11b positivity (> or = 10%) added prognostic value to clinical stages.
authors.affiliation: Postgraduate School of Hematology Farreras Valenti, Hospital Clíníc, Barcelona, Spain.
authors.forename: D
authors.initials: D
authors.lastname: Tàssies
authors.forename: E
authors.initials: E
authors.lastname: Montserrat
authors.forename: J C
authors.initials: JC
authors.lastname: Reverter
authors.forename: N
authors.initials: N
authors.lastname: Villamor
authors.forename: M
authors.initials: M
authors.lastname: Rovira
authors.forename: C
authors.initials: C
authors.lastname: Rozman
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015214:Antigens, Differentiation, Myelomonocytic / Q000378:metabolism*; D001402:B-Lymphocytes / Q000276:immunology; D016009:Chi-Square Distribution; D005260:Female; D005434:Flow Cytometry; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D016130:Immunophenotyping; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000097:blood / Q000276:immunology* / Q000473:pathology; D016177:Macrophage-1 Antigen / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D011379:Prognosis; D016016:Proportional Hazards Models
chemical_list: D015214:Antigens, Differentiation, Myelomonocytic; D006454:Hemoglobins; D016177:Macrophage-1 Antigen